Litt David, Slack Mary P E, Nakamura Tomoka, Gray Steve, Seaton Shila, Fagan Elizabeth J, Sheppard Carmen, Mwenda Jason M, Rey-Benito Gloria, Ghoniem Amany, Videbaek Dovile, Tondo Emanuel, Grabovac Varja, Serhan Fatima
Respiratory and Vaccine Preventable Bacteria Reference Unit, United Kingdom Health Security Agency (formerly Public Health England), London, UK.
World Health Organization Collaborating Centre for Haemophilus influenzae and Streptococcus pneumoniae, United Kingdom Health Security Agency (formerly Public Health England), London, UK.
J Med Microbiol. 2023 Jan;72(1). doi: 10.1099/jmm.0.001644.
In 2009, the World Health Organization (WHO) established the Global Invasive Bacterial Vaccine Preventable Disease (IB-VPD) Surveillance Network (GISN) to monitor the global burden and aetiology of bacterial meningitis, pneumonia and sepsis caused by (Hi), (Nm) and (Sp).. The GISN established an external quality assessment (EQA) programme for the characterization of Hi, Nm and Sp by culture and diagnostic PCR. To assess the performance of sentinel site laboratories (SSLs), national laboratories (NLs) and regional reference laboratories (RRLs) between 2014 and 2019 in the EQA programme. Test samples consisted of bacterial smears for Gram-staining, viable isolates for identification and serotyping or serogrouping (ST/SG), plus simulated cerebrospinal fluid (CSF) samples for species detection and ST/SG by PCR. SSLs and NLs were only required to analyse the slides for Gram staining and identify the species of the live isolates. RRLs, and any SLs and NLs that had the additional laboratory capacity, were also required to ST/SG the viable isolates and analyse the simulated CSF samples. Across the period, 69-112 SS/NL labs and eight or nine RRLs participated in the EQA exercise. Most participants correctly identified Nm and Sp in Gram-stained smears but were less successful with Hi and other species. SSLs/NLs identified the Hi, Nm and Sp cultures well and also submitted up to 56 % of Hi, 62 % of Nm and 33 % of Sp optional ST/SG results each year. There was an increasing trend in the proportion of correct results submitted over the 6 years for Nm and Sp. Some SSLs/NLs also performed the optional detection and ST/SG of the three organisms by PCR in simulated CSF from 2015 onwards; 89-100 % of the CSF samples were correctly identified and 76-93 % of Hi-, 90-100 % of Nm- and 75-100 % of Sp-positive samples were also correctly ST/SG across the distributions. The RRLs performed all parts of the EQA to a very high standard, with very few errors across all aspects of the EQA. The EQA has been an important tool in maintaining high standards of laboratory testing and building of laboratory capacity in the GISN.
2009年,世界卫生组织(WHO)建立了全球侵袭性细菌疫苗可预防疾病(IB-VPD)监测网络(GISN),以监测由b型流感嗜血杆菌(Hi)、脑膜炎奈瑟菌(Nm)和肺炎链球菌(Sp)引起的细菌性脑膜炎、肺炎和败血症的全球负担及病因。GISN建立了一个外部质量评估(EQA)计划,用于通过培养和诊断性聚合酶链反应(PCR)对Hi、Nm和Sp进行鉴定。为了评估2014年至2019年间哨点实验室(SSL)、国家实验室(NL)和区域参考实验室(RRL)在EQA计划中的表现。测试样本包括用于革兰氏染色的细菌涂片、用于鉴定和血清分型或血清群分组(ST/SG)的活菌分离株,以及用于通过PCR进行菌种检测和ST/SG的模拟脑脊液(CSF)样本。SSL和NL只需要分析革兰氏染色的玻片并鉴定活菌分离株的菌种。RRL以及任何具备额外实验室能力的SL和NL还需要对活菌分离株进行ST/SG并分析模拟CSF样本。在这期间,有69 - 112个SS/NL实验室以及8或9个RRL参与了EQA活动。大多数参与者在革兰氏染色涂片中能正确鉴定出Nm和Sp,但对Hi和其他菌种的鉴定成功率较低。SSL/NL能很好地鉴定Hi、Nm和Sp培养物,并且每年还提交高达56%的Hi、62%的Nm和33%的Sp的可选ST/SG结果。在这6年中,Nm和Sp提交的正确结果比例呈上升趋势。一些SSL/NL从2015年起也在模拟CSF中通过PCR对这三种微生物进行了可选检测和ST/SG;89 - 100%的CSF样本被正确鉴定,并且在所有分布中,76 - 93%的Hi阳性样本、90 - 100%的Nm阳性样本和75 - 100%的Sp阳性样本也被正确进行了ST/SG。RRL在EQA的所有部分都达到了非常高的标准,在EQA的各个方面错误都很少。EQA一直是在GISN中维持高标准实验室检测和建设实验室能力的重要工具。